Pioneering CRISPR-based medicines
CRISPR Therapeutics is a leading gene editing company co-founded by Emmanuelle Charpentier. The company made history with the first FDA-approved CRISPR therapy, Casgevy, for sickle cell disease and beta-thalassemia.
| Drug / Program | Indication | Phase | Technology |
|---|---|---|---|
| Casgevy (exa-cel) | Sickle Cell Disease | FDA Approved | CRISPR-Cas9 |
| Casgevy (exa-cel) | Beta-Thalassemia | FDA Approved | CRISPR-Cas9 |
| CTX110 | B-cell malignancies | Phase 2 | CRISPR-Cas9 |
| CTX112 | B-cell malignancies | Phase 1/2 | CRISPR-Cas9 |
| CTX310 | Cardiovascular | Phase 1 | CRISPR-Cas9 |
| VCTX210 | Type 1 Diabetes | Phase 1 | CRISPR-Cas9 |
A comprehensive look at the CRISPR companies shaping the future of medicine in 2026, from approved therapies to next-generation editing platforms.
Editas Medicine was the first CRISPR company, co-founded by Feng Zhang with Broad Institute patents. But while competitors won FDA approvals, Editas struggled. Here's what happened.
The gene editing market is projected to grow from $8.9 billion in 2024 to $45 billion by 2034 — a 17% CAGR. Here's where the growth is coming from and which segments will dominate.